May 8th 2024
A nurse-driven, verbal workflow to place tocilizumab orders contributed to safer and more effective delivery of tocilizumab for cytokine release syndrome.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
7th Annual Live Medical Crossfire®: Hematologic Malignancies
View More
Community Practice Connections™: Integrating BTK Inhibitors Into the CLL/SLL and MCL Treatment Paradigm
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Sagar Lonial Discusses Treating Patients With Myeloma
December 23rd 2015Sagar Lonial, MD, chief medical officer, Winship Cancer Institute of Emory University and Professor and Executive Vice Chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses treating patients with myeloma.
Daratumumab Combo Safe and Effective in Multiple Myeloma
December 8th 2015The CD38 monoclonal antibody daratumumab in combination with lenalidomide and dexamethasone proved to be safe and showed an 81% response rate in patients with relapsed or refractory multiple myeloma, according to research presented at the 2015 ASH Annual Meeting.
Ibrutinib Superior to Chemotherapy in Untreated Chronic Leukemia
December 7th 2015The kinase inhibitor Ibrutinib (Imbruvica) is a more effective frontline therapy than the traditional chemotherapy chlorambucil in treating older treatment-naïve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), reducing the risk of death by 84%.
Telephone Intervention Reduces Unplanned Hospitalizations for Patients With Blood Cancers
April 30th 2015A navigator-designed, proactive, weekly, telephone support call to help patients with blood cancers manage their symptoms between appointments was able to significantly reduce unplanned hospitalizations at a Colorado cancer center.
Low Vitamin D Levels Linked to Worse Outcomes in Follicular Lymphoma
April 14th 2015A new study has found that patients with lower vitamin D levels prior to treatment for follicular lymphoma are more likely to die or relapse from the disease earlier than patients with adequate vitamin D levels in their blood.
Dr. Shuo Ma Discusses Side Effects from New Treatments in NHL
March 9th 2015Shuo Ma, MD, PhD, assistant professor at Northwestern University in the Robert H. Lurie Comprehensive Cancer Center, discusses some of the side effects that come with new agents approved for the treatment of non-Hodgkin Lymphoma.
FDA's Panobinostat Approval Ushers in New Class of Drug to Treat Multiple Myeloma
March 5th 2015The FDA's approval of panobinostat (Farydak) for multiple myeloma, the first histone deacetylase (HDAC) inhibitor to be approved in this space, provides a new option and new hope for patients with this disease, Walter M. Capone, President and Chief Executive Officer of the Multiple Myeloma Research Foundation, said.